---
title: "Acadia Healthcare Shareholders Back Directors and Governance Proposals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285454029.md"
description: "Acadia Healthcare shareholders elected three directors at the annual meeting on May 6, 2026, ensuring continuity in governance. They approved amendments to the compensation plan and ratified Ernst & Young as the independent auditor for 2026. Analysts rate ACHC stock as a Buy with a $39.00 target, though Spark's AI Analyst gives it a Neutral rating due to recent financial losses and high leverage. Acadia operates a network of behavioral health facilities across the U.S. and Puerto Rico, focusing on mental health and addiction treatment services."
datetime: "2026-05-06T23:24:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285454029.md)
  - [en](https://longbridge.com/en/news/285454029.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285454029.md)
---

# Acadia Healthcare Shareholders Back Directors and Governance Proposals

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Acadia Healthcare ( (ACHC) ) has issued an update.

At its annual meeting of stockholders on May 6, 2026, Acadia Healthcare shareholders elected Daniel J. Cancelmi, Michael J. Fucci and Patrice A. Harris as Class III directors to serve until the 2029 annual meeting or until their successors are in place. The meeting results reinforced the company’s existing board composition and governance structure, signaling continuity in oversight as Acadia continues to operate its network of behavioral health facilities.

Stockholders also approved a second amendment to the company’s Amended and Restated Incentive Compensation Plan and gave non-binding advisory approval to the compensation of its named executive officers. In addition, shareholders ratified Ernst & Young LLP as Acadia’s independent registered public accounting firm for the fiscal year ending December 31, 2026, affirming the company’s executive pay practices and auditor relationship for the coming year.

The most recent analyst rating on (ACHC) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Acadia Healthcare stock, see the ACHC Stock Forecast page.

**Spark’s Take on ACHC Stock**

According to Spark, TipRanks’ AI Analyst, ACHC is a Neutral.

The score is held back primarily by weakened financial performance (large recent losses, higher leverage, and negative free cash flow). Offsetting this, the latest earnings call was constructive with a Q1 beat and raised full-year profitability guidance, while technicals show an improving intermediate trend. Valuation remains constrained by unprofitability and the lack of a dividend yield.

To see Spark’s full report on ACHC stock, click here.

**More about Acadia Healthcare**

Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries own and operate acute inpatient psychiatric hospitals, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and outpatient behavioral healthcare clinics. The company focuses on serving behavioral healthcare and recovery needs across communities in the U.S. and Puerto Rico, providing a broad continuum of mental health and addiction treatment services.

**Average Trading Volume:** 3,582,959

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $2.55B

For a thorough assessment of ACHC stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [ACHC.US](https://longbridge.com/en/quote/ACHC.US.md)

## Related News & Research

- [Acadia names David M. Duckworth interim CFO as Todd Young resigns](https://longbridge.com/en/news/283888231.md)
- [Acadia Healthcare (NASDAQ:ACHC) Releases Q1 2026 Earnings Guidance](https://longbridge.com/en/news/283901927.md)
- [Do Wall Street Analysts Like Welltower Stock?](https://longbridge.com/en/news/286776714.md)
- [Do Wall Street Analysts Like Thermo Fisher Scientific Stock?](https://longbridge.com/en/news/286749652.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)